Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2008

01.07.2008 | Epidemiology

Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans

verfasst von: Dezheng Huo, Hee-Jin Kim, Clement A. Adebamowo, Temidayo O. Ogundiran, Effiong E. Akang, Oladapo Campbell, Adeniyi Adenipekun, Qun Niu, Lise Sveen, James D. Fackenthal, Donna Lee Fackenthal, Soma Das, Nancy Cox, Anna Di Rienzo, Olufunmilayo I. Olopade

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

The UDP-glucuronosylatransferase 1A1 (UGT1A1) gene is involved in the metabolism of estrogen and detoxification of potential carcinogens. The number of TA repeats in the promoter region of UGT1A1 has been linked to breast cancer risk, but results varied by race. We performed a comprehensive assessment of genetic polymorphisms in the UGT1A1 gene, and examined these polymorphisms and TA repeats in relation to breast cancer risk in a case-control study in Nigeria. 512 breast cancer cases and 226 community controls were genotyped for UGT1A1. Compared with high-activity TA repeat genotypes, the odds ratios (OR) for low-activity and moderate-activity genotypes were 0.47 (95% confidence interval CI, 0.26–0.83) and 0.64 (95% CI, 0.39–1.06), respectively, in premenopausal women (P = 0.009 for trend), but no association was observed in postmenopausal women (P = 0.24). The effect of TA repeats was also differentiated by age: the OR was 0.39 (95% CI 0.21–0.71) for low-activity genotypes and 0.58 (95% CI 0.33–1.00) for moderate-activity genotypes in women <45 years old (P = 0.002 for trend), but no association was observed in women ≥45 years old (P = 0.15). Haplotype analysis showed that UGT1A1 haplotypes were highly diverse with blocked structures. We found a specific haplotype in block 2 that was significantly associated with a 2.1-fold elevated risk (95% CI 1.05–4.39; P = 0.04). In contrast with previous studies, we found low-activity TA repeat alleles were protective against breast cancer among premenopausal indigenous Africans, suggesting that the role of UGT1A1 in breast cancer development may vary by population, presumably due to different environmental and genetic modifier effects.
Literatur
1.
Zurück zum Zitat Tukey RH, Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581–616PubMedCrossRef Tukey RH, Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581–616PubMedCrossRef
2.
Zurück zum Zitat Mackenzie PI, Walter Bock K, Burchell B et al (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677–685PubMedCrossRef Mackenzie PI, Walter Bock K, Burchell B et al (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677–685PubMedCrossRef
3.
Zurück zum Zitat Senafi SB, Clarke DJ, Burchell B (1994) Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 303(Pt 1):233–240PubMed Senafi SB, Clarke DJ, Burchell B (1994) Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 303(Pt 1):233–240PubMed
4.
Zurück zum Zitat Guillemette C, Millikan RC, Newman B, Housman DE (2000) Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 60:950–956PubMed Guillemette C, Millikan RC, Newman B, Housman DE (2000) Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 60:950–956PubMed
5.
Zurück zum Zitat Bosma PJ, Chowdhury JR, Bakker C et al (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med 333:1171–1175PubMedCrossRef Bosma PJ, Chowdhury JR, Bakker C et al (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med 333:1171–1175PubMedCrossRef
6.
Zurück zum Zitat Guillemette C, De Vivo I, Hankinson SE et al (2001) Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol Biomarkers Prev 10:711–714PubMed Guillemette C, De Vivo I, Hankinson SE et al (2001) Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol Biomarkers Prev 10:711–714PubMed
7.
Zurück zum Zitat Shatalova EG, Loginov VI, Braga EA et al (2006) Association of polymorphisms in SULT1A1 and UGT1A1 Genes with breast cancer risk and phenotypes in Russian women. Mol Biol (Mosk) 40:263–270CrossRef Shatalova EG, Loginov VI, Braga EA et al (2006) Association of polymorphisms in SULT1A1 and UGT1A1 Genes with breast cancer risk and phenotypes in Russian women. Mol Biol (Mosk) 40:263–270CrossRef
8.
Zurück zum Zitat Adegoke OJ, Shu XO, Gao YT et al (2004) Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) and risk of breast cancer. Breast Cancer Res Treat 85:239–245PubMedCrossRef Adegoke OJ, Shu XO, Gao YT et al (2004) Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) and risk of breast cancer. Breast Cancer Res Treat 85:239–245PubMedCrossRef
9.
Zurück zum Zitat Cheng TC, Chen ST, Huang CS et al (2005) Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. Int J Cancer 113:345–353PubMedCrossRef Cheng TC, Chen ST, Huang CS et al (2005) Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. Int J Cancer 113:345–353PubMedCrossRef
10.
Zurück zum Zitat Balram C, Sabapathy K, Fei G, Khoo KS, Lee EJ (2002) Genetic polymorphisms of UDP-glucuronosyltransferase in Asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 12:81–83PubMedCrossRef Balram C, Sabapathy K, Fei G, Khoo KS, Lee EJ (2002) Genetic polymorphisms of UDP-glucuronosyltransferase in Asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 12:81–83PubMedCrossRef
11.
Zurück zum Zitat Innocenti F, Grimsley C, Das S et al (2002) Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725–733PubMedCrossRef Innocenti F, Grimsley C, Das S et al (2002) Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725–733PubMedCrossRef
12.
Zurück zum Zitat Beutler E, Gelbart T, Demina A (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95:8170–8174PubMedCrossRef Beutler E, Gelbart T, Demina A (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95:8170–8174PubMedCrossRef
13.
Zurück zum Zitat Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A (1999) Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 9:591–599PubMedCrossRef Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A (1999) Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 9:591–599PubMedCrossRef
14.
Zurück zum Zitat Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef
15.
Zurück zum Zitat Maitland ML, Grimsley C, Kuttab-Boulos H et al (2006) Comparative genomics analysis of human sequence variation in the UGT1A gene cluster. Pharmacogenomics J 6:52–62PubMedCrossRef Maitland ML, Grimsley C, Kuttab-Boulos H et al (2006) Comparative genomics analysis of human sequence variation in the UGT1A gene cluster. Pharmacogenomics J 6:52–62PubMedCrossRef
16.
Zurück zum Zitat Carlson CS, Eberle MA, Rieder MJ et al (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74:106–120PubMedCrossRef Carlson CS, Eberle MA, Rieder MJ et al (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74:106–120PubMedCrossRef
17.
Zurück zum Zitat Stephens M, Donnelly P (2003) A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162–1169PubMedCrossRef Stephens M, Donnelly P (2003) A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162–1169PubMedCrossRef
18.
Zurück zum Zitat Patil N, Berno AJ, Hinds DA et al (2001) Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science 294:1719–1723PubMedCrossRef Patil N, Berno AJ, Hinds DA et al (2001) Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science 294:1719–1723PubMedCrossRef
19.
Zurück zum Zitat Zhang K, Jin L (2003) HaploBlockFinder: haplotype block analyses. Bioinformatics 19:1300–1301PubMedCrossRef Zhang K, Jin L (2003) HaploBlockFinder: haplotype block analyses. Bioinformatics 19:1300–1301PubMedCrossRef
20.
Zurück zum Zitat Rubin DB (1987) Multiple imputation for nonresponse in surveys. Wiley, New York Rubin DB (1987) Multiple imputation for nonresponse in surveys. Wiley, New York
21.
Zurück zum Zitat Hong AL, Huo D, Kim HJ et al (2007) UDP-glucuronosyltransferase 1A1 gene polymorphisms and total bilirubin levels in an ethnically diverse cohort of women. Drug Metab Dispos 35:1254–1261PubMedCrossRef Hong AL, Huo D, Kim HJ et al (2007) UDP-glucuronosyltransferase 1A1 gene polymorphisms and total bilirubin levels in an ethnically diverse cohort of women. Drug Metab Dispos 35:1254–1261PubMedCrossRef
22.
Zurück zum Zitat Sparks R, Ulrich CM, Bigler J et al (2004) UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. Breast Cancer Res 6:R488–R498PubMedCrossRef Sparks R, Ulrich CM, Bigler J et al (2004) UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. Breast Cancer Res 6:R488–R498PubMedCrossRef
23.
Zurück zum Zitat Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN (1987) Bilirubin is an antioxidant of possible physiological importance. Science 235:1043–1046PubMedCrossRef Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN (1987) Bilirubin is an antioxidant of possible physiological importance. Science 235:1043–1046PubMedCrossRef
24.
Zurück zum Zitat Grant DJ, Bell DA (2000) Bilirubin UDP-glucuronosyltransferase 1A1 gene polymorphisms: susceptibility to oxidative damage and cancer? Mol Carcinog 29:198–204PubMedCrossRef Grant DJ, Bell DA (2000) Bilirubin UDP-glucuronosyltransferase 1A1 gene polymorphisms: susceptibility to oxidative damage and cancer? Mol Carcinog 29:198–204PubMedCrossRef
25.
Zurück zum Zitat Ching S, Ingram D, Hahnel R, Beilby J, Rossi E (2002) Serum levels of micronutrients, antioxidants and total antioxidant status predict risk of breast cancer in a case control study. J Nutr 132:303–306PubMed Ching S, Ingram D, Hahnel R, Beilby J, Rossi E (2002) Serum levels of micronutrients, antioxidants and total antioxidant status predict risk of breast cancer in a case control study. J Nutr 132:303–306PubMed
26.
Zurück zum Zitat Haiman CA, Hankinson SE, De Vivo I et al (2003) Polymorphisms in steroid hormone pathway genes and mammographic density. Breast Cancer Res Treat 77:27–36PubMedCrossRef Haiman CA, Hankinson SE, De Vivo I et al (2003) Polymorphisms in steroid hormone pathway genes and mammographic density. Breast Cancer Res Treat 77:27–36PubMedCrossRef
27.
Zurück zum Zitat Indap AR, Marth GT, Struble CA, Tonellato P, Olivier M (2005) Analysis of concordance of different haplotype block partitioning algorithms. BMC Bioinformatics 6:303PubMedCrossRef Indap AR, Marth GT, Struble CA, Tonellato P, Olivier M (2005) Analysis of concordance of different haplotype block partitioning algorithms. BMC Bioinformatics 6:303PubMedCrossRef
Metadaten
Titel
Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans
verfasst von
Dezheng Huo
Hee-Jin Kim
Clement A. Adebamowo
Temidayo O. Ogundiran
Effiong E. Akang
Oladapo Campbell
Adeniyi Adenipekun
Qun Niu
Lise Sveen
James D. Fackenthal
Donna Lee Fackenthal
Soma Das
Nancy Cox
Anna Di Rienzo
Olufunmilayo I. Olopade
Publikationsdatum
01.07.2008
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9720-7

Weitere Artikel der Ausgabe 2/2008

Breast Cancer Research and Treatment 2/2008 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.